Iterum Therapeutics Provides Regulatory Update
11 mai 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
25 avr. 2022 17h06 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 mars 2022 07h00 HE
|
Iterum Therapeutics plc
--Registration Trial for uUTI Planned in Second Half of 2022----Cash Runway into 2024-- --Company to host conference call today at 8:30am ET-- DUBLIN, Ireland and CHICAGO, March 28, 2022 (GLOBE...
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
21 mars 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 21, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
10 mars 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2022 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 déc. 2021 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer
13 déc. 2021 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 07h00 HE
|
Iterum Therapeutics plc
--Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024-- --Iterum to host conference call...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
05 nov. 2021 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...